Differently, to assess the long-term effect of SGLT2 inhibitors on the risk of AF/AFL more comprehensively and accurately, we included only RCTs with a follow-up duration of at least 52 weeks, along with some unpublished raw data from ClinicalTrials.gov (NCT03066830, NCT02926950, NCT03285594, NCT03332771, and NCT04065841), and incorporated the most recent publications. Here, SLC5A2 is linked to atrial fibrillation.